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Abstract
Background: Many men develop a rising PSA after initial therapy for prostate cancer. While some of these men will develop
a local or metastatic recurrence that warrants further therapy, others will have no evidence of disease progression. We
hypothesized that an expression biomarker panel can predict which men with a rising PSA would benefit from further
therapy.
Methodology/Principal Findings: A case-control design was used to test the association of gene expression with outcome.
Systemic (SYS) progression cases were men post-prostatectomy who developed systemic progression within 5 years after
PSA recurrence. PSA progression controls were matched men post-prostatectomy with PSA recurrence but no evidence of
clinical progression within 5 years. Using expression arrays optimized for paraffin-embedded tissue RNA, 1021 cancer-
related genes were evaluated–including 570 genes implicated in prostate cancer progression. Genes from 8 previously
reported marker panels were included. A systemic progression model containing 17 genes was developed. This model
generated an AUC of 0.88 (95% CI: 0.84–0.92). Similar AUCs were generated using 3 previously reported panels. In secondary
analyses, the model predicted the endpoints of prostate cancer death (in SYS cases) and systemic progression beyond
5 years (in PSA controls) with hazard ratios 2.5 and 4.7, respectively (log-rank p-values of 0.0007 and 0.0005). Genes mapped
to 8q24 were significantly enriched in the model.
Conclusions/Significance: Specific gene expression patterns are significantly associated with systemic progression after PSA
recurrence. The measurement of gene expression pattern may be useful for determining which men may benefit from
additional therapy after PSA recurrence.
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Introduction
The majority of men with prostate cancer are now diagnosed
with cancers that have a low risk of cause-specific mortality [1].
These men are usually treated with radical retropubic prostatec-
tomy (RRP), external beam radiotherapy, or interstitial brachy-
therapy and are then followed by regular serum PSA evaluations.
Over the next 5 to 10 year period, 15–30% of these men will
develop a rising PSA [2–6], defining a rapidly growing population
of major clinical and public health significance. Of this PSA
relapse group some men will have local recurrence or have
clinically-detectable metastasis, but many will have no other
evidence of recurrent prostate cancer other than the rising PSA.
The PSA ‘‘doubling time’’ has been identified as a potential
surrogate for cause-specific mortality, and is used by some
clinicians to determine which men with PSA relapse deserve
adjuvant hormonal ablation, local radiation therapy, or simple
observation [4–6]. Biomarkers that predict which of these men
would benefit from any additional therapy are needed.
Large scale gene expression studies of prostate cancers of different
grade and stage have been performed by several groups [7–16].
These expression studieshaveutilizedarrays containing probe setsof
up to 35,000 genes. While these studies are important for biomarker
discovery, several difficulties preclude their translation into a clincial
setting. First, it is likely that smaller panels will be used clinically.
Second, because the previous studies required frozen material, the
number of specimens analyzed was limited. Third, since adverse
clinical events in prostate cancer patients require lengthy followup,
the testing methods must be applicable to archival paraffin-
embedded material. Finally, none of the previous studies was
focused on the development of a biomarker panel to predict prostate
cancer systemic progression in the setting of PSA recurrence.
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(RRP) Registry, we designed a nested case-control study to test the
hypothesis that a limited set of RNA expression biomarkers can
predict which men with a rising PSA post-RRP might benefit from
additional clinical intervention. The Illumina DASL
TM expression
microarray platform was selected as the biomarker measurement
method, because it measures the expression of gene targets using
paraffin tissues [17–19]. Using expression data from the literature
and derived from our own research program we developed a
limited set of expression markers that would likely be altered in
association with prostate cancer progression. The panel also
included expression biomarkers from several other previously
published panels that are associated with surrogates (high Gleason
Score, high pathologic stage, or metastatic disease) for prostate
cancer aggressiveness [12–16].
We report that the array-based measurements showed excellent
correlation with quantitative RT-PCR measurements of paraffin-
derived RNAs. We also report excellent intra-array, inter-array
and within-gene reproducibility. We then describe the testing and
validation of a gene expression tissue biomarker panel for the
prediction of prostate cancer systemic progression following a
rising PSA after radical prostatectomy. We compare the
performance of our panel with other previously published panels.
Finally, we show that the overexpression of genes mapped to
chromosome band 8q24 is associated with prostate cancer
systemic progression.
Methods
Gene Selection and Array Design for the DASL
TM Assay
Two Illumina DASL expression microarrays were utilized
for the experiments. The standard commercially available
Illumina DASL expression microarray (Cancer Panel
TM v1)
containing 502 oncogenes, tumor suppressor genes and genes in
their associated pathways. Seventy-eight of the targets on the
commercial array have been associated with prostate cancer
progression.
A custom Illumina DASL
TM expression microarray containing
526 gene targets for RNAs, including genes whose expression is
altered in association with prostate cancer progression. Probes for
the custom DASLH panel were designed and synthesized by
Illumina, Inc. (San Diego, CA).
Four different sets of prostate cancer aggressiveness genes were
included in the study (if the genes were not present on the Cancer
Panel v1 array, they were included in the design of the custom
array):
1) Markers of prostate cancer aggressiveness identified by a
Mayo/University of Minnesota Partnership [20]: The
expression profiles of 100 laser-capture microdissected
prostate cancer lesions and matched normal and BPH
control lesions were analyzed using Affymetrix HG-U133
Plus 2.0 microarrays. Ranked lists of significantly over- and
under-expressed genes comparing 10 Gleason 5 and 7
metastatic lesions to 31 Gleason 3 cancer lesions were
generated. The top 500 genes on this list were compared to
lists generated from prior expression microarray studies and
other marker studies of prostate cancer (see 2–4 next). After
this analysis there was space for 204 novel targets with
potential association with aggressive prostate cancer on the
custom array.
2) Markers associated with prostate cancer aggressiveness from
publicly available expression microarray datasets (e.g.
EZH2, AMACR, hepsin, PRLz, PRL3): When we designed
the array sufficiently large datasets from 9 prior microarray
studies of prostate cancer of varying grades and metastatic
potential [7–15] were available from the Oncomine internet
site [21, 22], www.oncomine.org. From ordered lists of these
data we selected 32 genes for inclusion on the array.
3) Previously published markers associated with prostate
cancer aggressiveness (e.g. PSMA, PSCA, Cav-1): Expres-
sion microarray data has also been published. This literature
was evaluated for additional tissue biomarkers. For example,
at the time of array design we were able to identify 13 high
quality expression microarray studies of prostate cancer
aggressiveness (See Tables S1 and S2 for full reference list).
In addition, among the 13 reports, 5 papers presented 8
expression biomarker panels to predict prostate cancer
aggressiveness [12–16]. When appropriate probes suitable
for the DASL chemistry could be designed for these panels
they were included on the custom array. We also identified
12 articles reviewing genes associated with prostate cancer.
These criteria resulted in the selection of 150 genes.
4) Markers derived from Mayo SPORE research (including
genes and ESTs mapped to 8q24). Ninety-three additional
biomarkers were identified (see Tables S1 and S2).
The custom array also included probe sets for 45 genes that
were not expected to differ between case and control groups based
on Mayo/University of Minnesota Partnership data. Thirty-eight
of these genes were also present on the commercial array (see
Tables S1 and S2).
After enumerating the potentially prostate cancer relevant genes
on the commercially available cancer panel 570 potentially
prostate cancer relevant genes and 451 other cancer-related genes
were evaluated across both arrays.
Design of Nested Case-Control Study
For this study we sampled individuals from the Mayo Clinic
RRP Registry. The registry consists of a population of men who
received prostatectomy as their first treatment for prostate cancer
at the Mayo Clinic (For a current description and use of the
registry; see reference [23]). As systemic progression is relatively
infrequent, we designed a case-control study nested within a
cohort of men with a rising PSA. Between 1987–2001, inclusive,
9,989 previously-untreated men had RRP at Mayo. On follow-up,
2,131 developed a rising PSA (.30 days after RRP) in the absence
of concurrent clinical recurrence. PSA rise was defined as a follow-
up PSA .=0.20 ng/ml, with the next PSA at least 0.05 ng/ml
higher or the initiation of treatment for PSA recurrence (for
patients whose follow-up PSA was high enough to warrant
treatment). This group of 2,131 men comprises the underlying
cohort from which SYS cases and PSA controls were selected.
Within 5 years of PSA rise, 213 men developed systemic
progression (SYS cases), defined as a positive bone scan or CT
scan. Of these, 100 men succumbed to a prostate cancer-specific
death, 37 died from other causes and 76 remain at risk.
PSA recurrence controls (213) were selected from those men
without systemic progression within 5 years after the PSA rise and
were matched (1:1) on birth year, calendar year of PSA rise and
initial diagnostic pathologic Gleason score (,=6,7+). Twenty of
these men developed systemic progression greater than 5 years
after initial PSA rise and 9 succumbed to a prostate cancer-specific
death.
A set of 213 No Evidence of Disease (NED) Progression controls
were also selected from the Mayo Clinic RRP Registry of 9,989
men and used for some comparisons. These controls had RRP
from 1987–1998 with no evidence of PSA rise within 7 years of
A Prostate Cancer Marker Panel
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th,7 5
th percentile) follow-up from RRP was
11.3 (9.3, 13.8) years. The NED controls were matched to the
systemic progression cases on birth-year, calendar year of RRP
and initial diagnostic Gleason Score. Computerized optimal
matching was performed to minimize the total ‘‘distance’’ between
cases and controls in terms of the sum of the absolute difference in
the matching factors [24].
The current study was approved by the Institutional Review
Board of Mayo Clinic.
Block Identification, RNA Isolation, and Expression
Analysis
The list of 639 cases and controls was randomized. An attempt
was made to identify all available blocks (including apparently
normal and abnormal lymph nodes) from the randomized list of
639 eligible cases and controls. Maintaining the randomization,
each available block was assessed for tissue content by pathology
review and the block containing the dominant Gleason pattern
cancer was selected for RNA isolation.
Four freshly cut 10mm sections of FFPE tissue were depar-
affinized and the Gleason dominant cancer focus was macro-
dissected. RNA was extracted using the High Pure RNA Paraffin
Kit from Roche (Indianapolis, IN). RNA was quantified using ND-
1000 spectrophotometer from NanoDrop Technologies (Wilming-
ton, DE). The RNAs, including intra-plate and inter-plate
replicates, were distributed on 96-well plates in the randomized
order for DASL analysis.
RNA samples were processed,hybridized to Sentrix Universal 96-
Arrays, scanned using BeadArray Reader, and data initially
processed in BeadStudio according to the manufacturer’s instruc-
tions. Microarray data is available from the GEO database (http://
www.ncbi.nlm.nih.gov/geo/ accession number GSE10645).
To evaluate the accuracy of the gene expression levels defined
by the DASL technology, we performed quantitative SYBR Green
RT-PCR reactions for 9 selected ‘‘target’’ genes (CDH1, MUC1,
VEGF, IGFBP3, ERG, TPD52, YWHAZ, FAM13C1, and
PAGE4) and 4 commonly-used endogeneous control genes
(GAPDH, B2M, PPIA and RPL13a) in 384-well plates, with the
use of Prism 7900HT instruments (Applied Biosystems, Foster
City, CA). 210 RNA samples with abundant RNA from the group
of total 639 patients were analyzed. Because of RNA shortage,
only 77 samples were analyzed for PAGE4. mRNA was reverse-
transcribed with SuperScript III First Strand Synthesis SuperMix
(Invitrogen, Carlsbad, CA) using random hexamers. For each of
the nine genes studied, the cycle threshold (Ct) was determined in
triplicate and the expression was normalized relative to the set of
four reference genes.
Pathology Review
The Gleason score in the Mayo Clinic RRP Registry was
defined as the initial Gleason score. Since there have been changes
in pathologic interpretation of the Gleason score over time, a
single pathologist (JCC) reviewed the Gleason score of each of the
blocks selected for expression analysis. This clinical variable was
defined as the revised Gleason score.
Statistical Methodology
Collection of gene expression data was attempted for the 623
patients as described in Results. Of these, there were 596
(nSYS=200, nPSA=201, nNED=195) patients for whom data
was collected, the rest having failed one or both expression panels
as described in Results. To assure selection of similar training and
validation sets, 100 case-control-control cohorts comprised of 133
randomly chosen SYS patients (two-thirds of 200 for training)
along with their matched PSA and NED controls were selected as
a proposed training set. The remaining cases and controls were
treated as a proposed validation set. The clinical variables were
tested for independence between the proposed training and
validation sets separately within the SYS cases and the PSA
controls. Discrete clinical factors (pathologic stage, hormonal
treatment adjuvant to RRP, radiation treatment adjuvant to RRP,
hormonal treatment adjuvant to PSA recurrence, and radiation
therapy adjuvant to PSA recurrence) were tested using Chi–square
analysis. Continuous clinical variables (Gleason score (revised), age
at PSA recurrence, first rising PSA value, second rising PSA value,
and PSA slope) were tested using Wilcoxon rank sum. Six of the
one hundred randomly sampled sets failed to show dependency for
any of the clinical variables at the 0.2 level, and the first of these
was chosen as the training set: 391 patients (nSYS=133,
nPSA=133, nNED=125). This reserved 205 patients for the
validation set (nSYS=67, nPSA=68, nNED=70).
The raw data from BeadStudio was normalized using
cyclic loess (fastlo) [25]. The training data were analyzed
using random forests [26] using R Version 2.3.1 (http://www.r-
project.org) and randomForest version 4.5–16 (http://stat-www.
berkeley.edu/users/breiman/RandomForests). The data were
analyzed by panel (Cancer, Custom and Merged, where Merged
was the Cancer and Custom data treated as a single array). By
testing the ntree parameter of the randomForest function we
determined that 4000 random forests were sufficient to generate a
stable list of markers. The top markers as sorted for significance by
the randomForest program were combined with various
combinations of clinical variables using logistic regression R
program (glm() with family=binary (a logistic model), where glm
refers to generalized linear model). The resulting scoring function
was then analyzed using Receiver Operating Characteristic (ROC)
methods and the cut-off was chosen that assumed an equal penalty
for false positives and false negatives. A review of the models
permitted a subset of markers to be identified, and a subset of
supporting clinical data identified. The number of features in the
model was determined by leave 1/3 out Monte Carlo Cross
Validation (MCCV) using 100 iterations. The number of features
was selected to maximize AUC and minimize random variation in
the model. The final model was then applied to the 391 patient
training set and the reserved 205 patient validation set. For
comparison, other previously reported gene expression models
were also tested against the training and validation sets [12–16].
We compared the previously reported models for their
classification of patients into the known PSA recurrence control
and SYS progression case groups. We used the Crame ´r’s V-
statistic [27] to compare models.
Results
Study Design/Paraffin Block Recovery/RNA Isolation and
Expression Panel Success
Briefly, a nested case-control study was performed using the
large, well-defined cohort of men with rising PSA following
RRP(Figure S1). SYS cases were 213 men who developed systemic
progression between 90 days and 5.0 years following the PSA rise.
PSA controls were a random sample of 213 men who were 5 years
post-RRP with PSA recurrence but with no evidence of further
clinical progression. NED controls were a random sample of 213
men who were 7 years post-RRP without PSA rise (the
comparison of PSA controls with NED controls-will be presented
in a subsequent paper). SYS cases and PSA controls were matched
(1:1) for birth year, calendar year of PSA rise, and initial
A Prostate Cancer Marker Panel
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cases and controls was randomizeed for the blind ascertainment of
blocks, isolation of RNA and performance of the expression array
experiments.
Table 1 summarizes the distribution of clinical parameters
between the SYS cases and the PSA and NED control groups.
There was no significant difference between the groups for the
matching variables (there was no significant difference in initial
diagnostic Gleason score when the ,=6 and .7 groups-the
matching criteria-were compared). Comparison of the initial
diagnostic Gleason score to the revised Gleason scores revealed
that Gleason scores have increased over time. In addition, the
proportion of Gleason 8–10 tumors increased comparing NED
controls to PSA controls, and PSA controls to SYS cases. The
revised Gleason score was used in all the biomarker modeling.
All paraffin-embedded blocks from eligible men were identified
and each block was surveyed for the tissue present (primary and
secondary Gleason cancer regions, normal and metastatic lymph
nodes, etc.). We macrodissected the dominant Gleason pattern
region and attempted to isolate RNA. Illumina Cancer Panel
TM
and custom prostate cancer panel DASL array analyses were then
performed on all RNA specimens. The Methods section and
Table 1. Systemic progression (SYS) Case and PSA recurrence (PSA) and no evidence of disease (NED) control patient
demographics
Progression group p-value
NED controls PSA controls SYS cases NED vs. PSA PSA vs. SYS
Year of Surgery 0.707 0.592
N 213 213 213
Median 1992 1992 1992
Q1, Q3 1989, 1995 1990, 1995 1989, 1995
Age at RRP 0.682 0.496
N 213 213 213
Median 67 67 67
Q1, Q3 61, 70 61, 70 61, 70
PSA at RRP 0.001 0.957
N 205 208 204
Median 8.1 10.5 10.6
Q1, Q3 5.1, 13.1 6.4, 21.4 6.5, 20.7
Gleason score, original 0.411 0.024
Missing 12 6 14
,=6 45 (22.4%) 48 (23.2%) 46 (23.1%)
7 139 (69.2%) 129 (62.3%) 94 (47.2%)
8–10 17 (8.5%) 30 (14.5%) 59 (29.6%)
Gleason score, revised 0.002 ,0.001
Missing 8 2 6
,=6 50 (24.4%) 32 (15.2%) 8 (3.9%)
7 114 (55.6%) 113 (53.6%) 75 (36.2%)
8–10 41 (20.0%) 66 (31.3%) 124 (59.9%)
Pathologic stage 0.138 ,0.001
T2N0 118 (55.4%) 95 (44.6%) 59 (27.7%)
T3aN0 43 (20.2%) 53 (24.9%) 47 (22.1%)
T3bN0 21 (9.9%) 54 (25.4%) 56 (26.3%)
T3xN+ 31 (14.6%) 11 (5.2%) 51 (23.9%)
Ploidy 0.525 0.001
Missing 13 9 1
Diploid 136 (68.0%) 128 (62.7%) 97 (45.8%)
Tetraploid 53 (26.5%) 61 (29.9%) 84 (39.6%)
Aneuploid 11 (5.5%) 15 (7.4%) 31 (14.6%)
Age at PSA recurrence NA 0.558
N 213 213
Median 69.1 69.6
Q1, Q3 64.2, 73.4 64.7, 73.8
doi:10.1371/journal.pone.0002318.t001
A Prostate Cancer Marker Panel
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the design of the custom panel.
Table 2 summarizes the final block availability, the RNA isolation
success rate and the success rates of the expression array analyses. Of
the 639 eligible patients, blocks were available on 623 (97.5%). RNA
was isolated and DASL assays successfully performed on a high
proportion of patients/specimens: usable RNA was prepared from
all 623 blocks, and the Cancer Panel and custom panel DASL arrays
were both successful (after repeating some specimens–see below) on
596 RNA specimens (95.7% of RNAs; 93.3% of design patients).
Only 9 (1.4%) RNA specimens failed both panels. The primary
reason for these failures was poor RNA quality–as measured by
qRT-PCR of the RPL13a gene expression [19]. Of the 1246 initial
samples run on both panels, 87 (7.0%) specimens failed. Those
specimens for which there was residual RNA were repeated with a
success rate of 77.2% (61 of 79 samples).
Expression Analysis Reproducibility
Replicate analysis results (Figure S2), RT-PCR comparisons
(Figure S3) and inter- and intra-panel gene expression compar-
isons are described in Results S1.
Specific Gene Expression Results Comparing the
Systemic Progression Cohorts with the PSA Recurrence
and No Evidence of Progression Cohorts
Univariate Analyses by gene. Because the DASL assay
appeared to generate precise and reproducible results, the array
data was examined for genes whose expression was significantly
altered when the SYS cases were compared with the PSA controls.
For this initial analysis, the DASL gene expression value was
determined to be the average of up-to-three probes for each gene
on each array. Upon univariate analysis (two-tail t-test) of the
probe-averaged and fastlo normalized data [25], 68 genes were
highly significantly over- or under-expressed in the SYS cases
versus PSA controls (p,9.73610
27, Bonferroni correction for
p,0.001) (Table 3). One hundred twenty-six genes were
significantly over- or under-expressed in the SYS cases versus
the PSA controls (p,4.86610
25, Bonferroni correction for
p,0.05). Table S3 provides the complete gene list ordered by p-
value. Figure 1 illustrates nine genes with significantly different
expression in the SYS cases and PSA controls.
Systemic Progression Prediction Model Development and
Testing on a Training set. A statistical model to predict
systemic progression (with and without clinical variables) using a
training set was developed using random forests [21] and logistic
regression as described in Methods. The training data were
analyzed by panel (cancer, custom and merged), by gene (the
average expression for all gene-specific probes), and by individual
probes. Table 4 lists the 15 genes and 2 individual probes selected
for the final model.
Table 5 and Figure 2A summarize the areas under the curve
(AUCs) for three clinical models, the final 17 gene/probe model
and the combined clinical probe models. The variables in the
clinical models (Table 6) were based on available clinical
information. Clinical model A included revised Gleason score
and pathologic stage (information available immediately after
RRP). The addition of diagnostic PSA and age at surgery did not
significantly add to the AUC and was left out of this model (data
not shown). Clinical model B added age at surgery, preoperative
PSA value, and any adjuvant or hormonal therapy within 90 days
after RRP (information available after RRP but before PSA
recurrence). Clinical model C added age at PSA recurrence, the
second PSA level at time of PSA recurrence, and the PSA slope
(information available at the time of PSA recurrence).
Using the training set, clinical models A, B and C alone had
AUCs of 0.74 (95% CI 0.68–0.80), 0.76 (95% CI 0.70–0.82) and
0.78 (95% CI 0.73–0.84), respectively. The 17 gene/probe model
alone had an AUC of 0.85 (95% CI 0.81–0.90). When combined
with the 17 gene/probe model, clinical models A, B, and C had
AUCs of 0.86 (95% CI 0.81–0.90), 0.87 (95% CI 0.83–0.91) and
0.88 (95% CI 0.84–0.92), respectively. We also tested a 19 gene
model that added TOP2A and survivin (BIRC5) to the17 gene/
probe model. The addition of these two genes did not improve the
prediction of systemic progression in the training set (data not
shown).
The arrays were selected to include probe sets for several
previously published prostate aggressiveness models [12–16].
Table 5 summarizes the AUCs for array expression results for
these biomarker models. Figure 2C illustrates the AUCs for four of
these models with the appropriate comparison with clinical model
C and with the 17 gene/probe model. Each of these models
generated AUCs that were smaller than the model we developed.
However several of the models generated AUCs (e.g. the Lapointe
et al. 2004 recurrence, Yu et al. 2004, and Singh et al. 2002
models) that were within or close to the 95% confidence limits of
our AUC training set estimates.
Testing of Models on the Validation Set. We then applied
the 17 gene/probe model and the other previously published
models to the reserved 205 patient validation set (Figures 2B and
2D). Figure 2E compares the training set and validation set AUCs
of the each of gene/probe models. With the exception of the
Glinsky et al. 2004 Signature 1, all of the gene/probe models had
significantly lower AUCs in the validation set compared to the
training set. Figure 2F compares the training and validation set
AUCs of each of the gene/probe models including clinical model
C. While the 17 gene/probe model and three of the previously
published models (the LaPointe et al. 2004 recurrence, Yu et al.
2004, and Glinsky et al. 2005 models) outperformed the clinical
model alone, the AUCs were significantly lower in the validation
set compared to the training set.
We also compared the models for their classification of patients
into the known PSA recurrence control and SYS progression case
groups. Table S4 summarizes the Crame ´r’s V-statistic [27] of the
various models, and includes a perfect predictor (‘‘truth’’) model
for direct evaluation of the models. Briefly, the Crame ´r’s V-
statistic ranged from 0.38 to 0.70. The lowest Crame ´r’s V-statistic
was between the true state (perfect prediction) and the Glinsky et
al. 2005 model with clinical data. The highest Crame ´r’s V value
was between our 17 gene/probe model and Singh et al. 2002
Table 2. Availability of blocks, RNA isolation success and
DASL assay success
Progression Case/
Control Group
None PSA Systemic Total
Design Number 213 213 213 639
Blocks Available 205 211 207 623 (97.5%)
Usable RNA 205 211 207 623 (100%)
Evaluable Data, Both DASL Panels 195 201 200 596 (95.7%)
Evaluable Data, 3 5 2 10 (1.6%)
Evaluable Data, 2 3 3 8 (1.3%)
Failed Both Panels 5 2 2 9 (1.4%)
doi:10.1371/journal.pone.0002318.t002
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correction p,9.73E-07)
DASL fast-lo Normalized Expression Value
rank Gene Symbol Gene ID* Systemic Progression PSA Recurrence SYS to PSA Fold Change SYS to PSA p-value**
1 RAD21*** NM_006265 7587 6409 1.18 8.57E-14
2 YWHAZ NM_145690 15625 13417 1.16 1.92E-13
3 TAF2*** NM_003184 3144 2681 1.17 6.99E-13
4 SLC44A1 NM_080546 4669 4022 1.16 2.74E-12
5 IGFBP3 NM_000598 4815 3782 1.27 3.75E-12
6 RHOA NM_001664 15859 14542 1.09 1.22E-11
7 MTPN NM_145808 7646 6840 1.12 1.69E-11
8 BUB1 NM_001211 1257 957 1.31 2.07E-11
9 TUBB NM_178014 17412 15659 1.11 6.52E-11
10 CHRAC1*** NM_017444 3905 3233 1.21 6.74E-11
11 HPRT1 NM_000194 3613 3179 1.14 8.19E-11
12 SEC14L1 NM_003003 7248 6185 1.17 8.20E-11
13 SOD1 NM_000454 17412 16043 1.09 1.30E-10
14 ENY2 NM_020189 7597 6493 1.17 2.04E-10
15 CCNB1 NM_031966 1871 1342 1.39 3.65E-10
16 INHBA NM_002192 4859 3732 1.30 5.18E-10
17 TOP2A NM_001067 5550 4123 1.35 7.42E-10
18 ATP5J NM_001003703 13145 11517 1.14 1.75E-09
19 C8orf53*** NM_032334 7373 6444 1.14 1.88E-09
20 EIF3S3*** NM_003756 11946 10798 1.11 1.98E-09
21 EIF2C2*** NM_012154 5908 5338 1.11 2.12E-09
22 CDKN3 NM_005192 1562 1229 1.27 2.32E-09
23 TPX2 NM_012112 1193 861 1.39 2.64E-09
24 GLRX2 NM_197962 4154 3319 1.25 3.13E-09
25 CTHRC1 NM_138455 3136 2480 1.26 3.83E-09
26 KIAA0196*** NM_014846 5530 4945 1.12 4.12E-09
27 DHX9 NM_030588 7067 6607 1.07 5.02E-09
28 FAM13C1 NM_001001971 4448 5416 0.82 9.07E-09
29 CSTB NM_000100 16424 15379 1.07 1.57E-08
30 SESN3.a SESN3.a 8467 6811 1.24 1.99E-08
31 SQLE*** NM_003129 2282 1832 1.25 2.43E-08
32 IMMT NM_006839 4683 4190 1.12 2.43E-08
33 MKI67 NM_002417 4204 3261 1.29 2.91E-08
34 MRPL13*** NM_014078 5051 4158 1.21 3.80E-08
35 SRD5A2 NM_000348 2318 2795 0.83 4.63E-08
36 EZH2 NM_004456 3806 3257 1.17 4.76E-08
37 F2R NM_001992 3856 3203 1.20 5.61E-08
38 SH3RF2.a SH3RF2 1394 1705 0.82 6.48E-08
39 ZNF313 NM_018683 9542 8766 1.09 7.14E-08
40 SDHC NM_001035511 2363 2082 1.14 7.35E-08
41 PGK1 NM_000291 2313 2001 1.16 7.84E-08
42 GNPTAB NM_024312 5427 4587 1.18 9.04E-08
43 meelar.d meelar.d 2566 3478 0.74 9.59E-08
44 THBS2 NM_003247 3047 2458 1.24 9.72E-08
45 BIRC5 NM_001168 2451 1802 1.36 1.00E-07
46 POSTN NM_006475 7210 5812 1.24 1.02E-07
47 GNB1 NM_002074 12350 11206 1.10 1.20E-07
48 FAM49B*** NM_016623 6291 5661 1.11 1.21E-07
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same patients into the known groups (e.g. classifying a patient in
the PSA control group as a PSA recurrence and a patient in the
SYS case group as a systemic progression). They also tended to
incorrectly classify the same patients (e.g classifying a patient in the
PSA control group as a systemic progression and vice versa). The
17 gene/probe model correctly classified 5–15 more patients into
their known category (PSA controls or SYS cases) compared to the
other models (data not shown).
Secondary Analyses
Exploratory Survival studies. As noted above, the 17 gene/
probe model and the previously reported models each classified
some of the SYS cases in the good outcome category (e.g. to be PSA
recurrences, not systemic progressors) and some of the PSA controls
in the poor outcome category (e.g. to go on to systemic progression).
We were curious to know whether these apparently false
classifications had any biologic or clinical relevance.
Seventeen men in the PSA control group (who had both array
and clinical model C data) went on to have systemic progression
beyond 5 years at the time of last follow-up. Of these 17 patients, 9
were predicted to have a poor outcome by the 17 gene/probe
model. Of the 179 patients who did not have any systemic
progression, 38 were classified in the poor outcome category by
the model (p value=0.0066, Fisher exact test). Figure 3A
illustrates the systemic progression-free survival for the good and
poor outcome groups in the PSA controls. PSA controls with a
Table 3. cont.
DASL fast-lo Normalized Expression Value
rank Gene Symbol Gene ID* Systemic Progression PSA Recurrence SYS to PSA Fold Change SYS to PSA p-value**
49 WDR67*** NM_145647 1655 1423 1.16 1.67E-07
50 TMEM65.a TMEM65.a 4117 3540 1.16 1.96E-07
51 GMNN NM_015895 7458 5945 1.25 1.99E-07
52 PAGE4 NM_007003 6419 8065 0.80 2.00E-07
53 MYBPC1 NM_206821 8768 11120 0.79 2.61E-07
54 GPR137B NM_003272 3997 3447 1.16 2.96E-07
55 ALAS1 NM_000688 5380 5035 1.07 3.55E-07
56 MSR1 NM_002445 3663 3025 1.21 3.65E-07
57 CDC2 NM_033379 1420 1130 1.26 3.90E-07
58 240093_x_at 240093_x_at 1789 1469 1.22 4.71E-07
59 IGFBP3 NM_000598 10673 9433 1.13 4.85E-07
60 RAP2B NM_002886 3270 2922 1.12 5.00E-07
61 MGC14595.a*** MGC14595.a 2252 1995 1.13 5.46E-07
62 AZGP1 NM_001185 17252 20133 0.86 6.55E-07
63 NOX4 NM_016931 2321 1942 1.19 6.67E-07
64 STIP1 NM_006819 7630 7123 1.07 7.23E-07
65 PTPRN2 NM_130843 4471 5398 0.83 7.36E-07
66 CTNNB1 NM_001904 9989 9354 1.07 7.50E-07
67 C8orf76*** NM_032847 4088 3652 1.12 7.88E-07
68 YY1 NM_003403 9529 8635 1.10 8.08E-07
*The Gene ID is the accession number when available. Other Gene IDs can be found by searching the May 2004 assembly of the human genome at http://genome.ucsc.
edu/cgi-bin/hgGateway.
**t-test
***Genes mapped to 8q24
doi:10.1371/journal.pone.0002318.t003
Figure 1. Nine genes with significantly different expression in
cases with systemic disease progression (SYS) versus controls
with PSA recurrence (PSA). P-values (t-test) for the SYS case/PSA
control comparison are shown. Controls with no evidence of disease
recurrence (NED) are also included.
doi:10.1371/journal.pone.0002318.g001
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increased risk for developing systemic progression beyond 5 years
(log rank p-value=0.00050) (HR=4.7, 95% CI: 1.8–12.1).
Ninety-three men in the SYS case group (who also had array
and clinical model C data) went on to prostate cancer death at the
time of last follow-up. Of these 93 patients, 78 were predicted to
have a poor outcome by the 17 gene/probe model. Of the 98
patients who did not suffer a prostate cancer death, 61 were
classified in the poor outcome category by the model (p
value=0.0008, chi-square test). Figure 3B illustrates the prostate
cancer-specific overall survival for the good and poor outcome
groups in the SYS cases. SYS cases with a tumor classified as
having a poor outcome had significantly increased risk for
suffering a prostate cancer-specific death (HR=2.5, 95% CI:
1.5–4.4). The median survival from first positive bone scan or CT
was 2.8 years (95% CI: 2.4–4.2) in the group classified as having a
poor outcome and 8.6 years (95% CI: 7.4–‘) in the group
classified as having a good outcome (log rank p-value=0.00068).
Similar associations were observed when three of the previously
published models with high AUCs (the Lapointe et al. 2004
recurrence, Yu et al. 2004, and Glinsky et al. 2005 models) were
evaluated. The following describes the results for the LaPointe et
al. 2004 recurrence model (data for the other two models were
similar and are not shown). Of the 98 patients who did not suffer a
prostate cancer death, 60 were predicted to have a poor outcome
by the Lapointe et al. 2004 recurrence model (p value=0.0001,
chi-square test). Figure 3C illustrates the prostate cancer-specific
overall survival for the good and poor outcome groups in the SYS
cases. SYS cases whose tumor classified as having a poor outcome
had significantly increased hazard of suffering a prostate cancer-
specific death (HR=2.3, 95% CI: 1.3–4.2). The median survival
from first positive bone scan or CT was 3.1 years (95% CI: 2.5–
4.3) in the group classified as having a poor outcome and 8.6 years
(95% CI: 8.3–‘) in the group classified as having a good outcome
(log rank p-value=0.0033).
Table 4. Final random forest 17 gene/probe model to predict prostate cancer systemic progression after a rising PSA following
radical prostatectomy
Mean DASL Expression Values
Rank (t-test) Symbol Mean Gini Decrease* p-value (t-test) Systemic Progression PSA Recurrence Systemic:PSA Fold Change
1 RAD21** 2.15 8.57E-14 7587 6409 1.18
22 CDKN3 1.28 2.32E-09 1562 1229 1.27
15 CCNB1 1.25 3.65E-10 1871 1342 1.39
12 SEC14L1 1.14 8.20E-11 7248 6185 1.17
8 BUB1 1.06 2.07E-11 1257 957 1.31
55 ALAS1 1.04 3.55E-07 5380 5035 1.07
26 KIAA0196** 1.02 4.12E-09 5530 4945 1.12
3 TAF2** 1.02 6.99E-13 3144 2681 1.17
78 SFRP4 0.99 1.89E-06 15176 13059 1.16
64 STIP1 0.95 7.23E-07 7630 7123 1.07
25 CTHRC1 0.90 3.83E-09 3136 2480 1.26
4 SLC44A1 0.90 2.74E-12 4669 4022 1.17
5 IGFBP3 0.85 3.75E-12 4815 3782 1.27
307 EDG7 0.82 7.07E-03 5962 6757 0.88
48 FAM49B** 0.82 1.21E-07 6291 5661 1.11
19 C8ORF53** 0.97*** 1.88E-09 7373 6444 1.14
275 CDK10 0.53*** 4.12E-03 12254 12868 0.95
*Mean Gini Decrease for a variable is the average (over all random forest trees) decrease in node impurities from recursive partitioning splits on that variable. For
classification, the node impurity is measured by the Gini index. The Gini index is the weighted average of the impurity in each branch, with impurity being the
proportion of incorrectly classified samples in that branch. The larger the Gini decrease, the fewer the misclassification impurities.
**Genes mapped to 8q24
***Single probes for C8orf53 and CDK10 were selected. The Mean Gini Decrease for these probes are derived from an independent random forest analysis of thea l l
probes separately.
doi:10.1371/journal.pone.0002318.t004
Table 5. Prediction of systemic progression–training set
AUCs
Probes
alone Clinical model*
ABC
Clinical model alone NA 0.736 0.757 0.783
Final 17 gene/probe 0.852 0.857 0.873 0.883
Glinsky et al. 2004 Signature 1 0.665 0.762 0.776 0.798
Glinsky et al. 2004 Signature 2 0.638 0.764 0.781 0.798
Glinsky et al. 2004 Signature 3 0.669 0.770 0.788 0.810
Glinsky et al. 2005 0.729 0.780 0.800 0.811
Lapointe et al. 2004 Tumor Recurrence Sig. 0.789 0.825 0.838 0.855
Lapointe et al. 2004 (MUC1 and AZGP1) 0.660 0.767 0.777 0.793
Singh et al. 2002 0.783 0.824 0.838 0.851
Yu et al. 2004 0.725 0.797 0.815 0.830
*See Table 6 for clinical variables included in the clinical models
doi:10.1371/journal.pone.0002318.t005
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PLoS ONE | www.plosone.org 8 May 2008 | Volume 3 | Issue 5 | e2318Figure 2. Areas under the curve (AUCs) for three clinical models, the final 17 gene/probe model and the combined clinical probe
models. A. The training set AUCs for three clinical models, the final 17 gene/probe model and the combined clinical/17 gene/probe model. B. The
validation set AUCs for three clinical models, the final 17 gene/probe model and the combined clinical/17 gene/probe model. C. The training set
AUCs of 4 previously reported gene expression models of prostate cancer aggressiveness compared with the clinical model C alone and with the 17
gene/probe model. D. The validation set AUCs of 4 previously reported gene expression models of prostate cancer aggressiveness compared with the
clinical model C alone and with the 17 gene/probe model. For an explanation of the clinical models see Table 6. (E and F) A comparison of the
training and validation set AUCs for each of the model. E. AUCs of the each of the gene/probe models alone. F. AUCs of each of the gene/probe
models with the inclusion of clinical model C.
doi:10.1371/journal.pone.0002318.g002
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chromosome dosage and germ line association studies, the custom
array included 82 8q genes on the custom array. Fourteen 8q genes
were within the top 68 genes based upon univariate analysis
(Table 3). Compared to the proportion of 8q genes on both arrays
the prevalence of 8q genes is non random (p=0.003, Fisher exact
test). Twelve additional 8q genes were within the top 126 genes. The
prevalence of 26 8q genes in the top 126 is statistically significant
(p=1.56610
25, Fisher exact test). Chromosome band 8q24.1 has
the greatest overrepresentation of genes in the top 68 gene and 126
gene lists (11 genes, p=6.35610
27 and 19 genes, p=9.34610
212,
Fisher exact test). Of the 17 genes/probes in our final model, five
map to 8q24 (p=0.0043, Fisher exact test)(see Table 4).
Exploratory ets Transcription Factor Studies. Alterations
of several ets-family oncogenes are associated with the development
of prostate cancer [28–30]. We included oligonucleotide probe sets
for the three major members of the ets family involved in prostate
cancer: ERG, ETV1, and ETV4, as well as their translocation
partner TMPRSS2. Figure 4 summarizes the expression results for
these genes for the SYS cases and the PSA and NED controls.
Several observations can be made: 1) With only 8 exceptions ERG,
ETV1 and ETV4 overexpression are mutually exclusive; i.e. the
overexpression of each generally occurs in different tumors. 2)
Different probe sets for ERG give nearly identical expression results
(see Figure S4A). 3) The prevalence of ERG overexpression was
50.0%, 52.2% and 53.8% in the SYS cases, PSA controls and NED
controls, respectively. There was no significant difference in the
mean expression and the prevalence of ERG overexpression
between the three cohorts (see Figure 4). 4) The prevalence of
ETV1 overexpression was 11.5%, 6.5% and 5.1% in the SYS cases,
PSA controls and NED controls, respectively (see Figure 4). The
prevalence of ETV1 overexpression was significantly higher in SYS
cases (p=0.043, chi-square test). 5) The prevalance of ETV4
overexpression ranged from 2.5%–5.5% among the three groups
and wasnot significantlydifferent.6)None of thegeneswere selected
by the formal statistical modeling (see Table 4). In fact, the 17 gene/
probe model predicted similar rates of progression in ERG+ and
ERG-patients (data not shown).
Exploratory Pathway Analysis. We used the 461 genes
from both cancer and custom panels that are potentially
differentially expressed between SYS cases and PSA controls
(p#0.05) as the focus genes for Ingenuity Pathway Analysis (IPA,
Ingenuity Systems Inc. Redwood City, CA). IPA identified 101
canonical pathways that are associated with the focus genes, 51 of
which are overrepresented with p#0.05 (see Table S5). However,
because we measured a limited number of genes on both DASL
panels, the p values from IPA analysis may not accurately quantify
the degree of overrepresentation of focus genes in each pathway.
We then performed Gene Set Enrichment Analysis (GSEA)
[31], on chromosome 8 genes grouped by map location. Genes
mapped to 8q24.1 had a significant p value (p=0.0002) with a
FDR q value=0.001 (see Table S6).
Discussion
Patients with a rising PSA following definitive therapy comprise
a heterogeneous cohort; a significant number develop metastasis,
followed by hormone refractory prostate cancer. Of these, a
substantial number, but not all, will die of the disease. PSA failure
following RRP or radiation therapy is associated with a 15% to
25% five year prostate cancer death rate [32,33]. Androgen
deprivation has been increasingly used in all stages of prostate
cancer to improve mortality rates [34,35] or to facilitate prostate
cytoreduction [36,37]. Two recent studies described the natural
history of progression after PSA elevation following RRP or
radiation therapy [32,38]. They identified PSA doubling time as a
potential surrogate for prostate mortality. In three retrospective
studies early androgen deprivation in patients with biochemical
failure and short (,12 months) PSA doubling time after
prostatectomy improved survival [39–41]. We hypothesized that
additional biomarkers beyond PSA doubling time could help
predict which men with a rising PSA post-RRP might suffer
systemic progression. Such a panel could be incorporated into
future prospective clinical trials in the setting of PSA progression.
Using an array methodology optimized for RNA from paraffin-
embedded tissues and a rigorous statistical modeling algorithm, we
developed a 17 gene/probe tissue gene expression model to
predict the likelihood of systemic progression in men with a rising
PSA post-RRP. In a training set the 17 gene/probe model was
significantly better than the use of clinical variables alone. While
accuracy decreased when the 17 gene/probe model was further
tested with a reserved validation set, the performance of the 17
gene/probe model with clinical model C was better than the
clinical model alone.
The reduction in AUC between the training and validation sets
was in part due to the overfitting inherent in these types of
analyses. Since we maximized the AUC on the training set, the
validation set AUC would be predicted to be lower. Another cause
of the reduction in AUC could be a relative lack of precision of the
Illumina DASL technology. Except for the poor correlation of the
DASL and RT-PCR measurements for genes with low DCt values,
all of the intra-plate, inter-plate, intra-gene and inter-gene
reproducibility analyses suggested that the DASL chemistry was
very precise. We observed greater coefficients of variation in our
replicate RT-PCR measurements than in the DASL measure-
ments (data not shown).
Perhaps the best explanation for the validation set AUC reduction
is that prostate cancer is genetically heterogeneous. This heteroge-
neity can result in a reduction in a validation set AUC even for
relatively large datasets. This hypothesis predicts that several
different models could be developed from the same dataset. One
of the advantages of the Illumina DASL platform is its ability to
analyze up to 1536 probes (or 512 genes if thee probes are selected
per gene) on a single array. We included probes from eight
previously reported gene expression panels associated with prostate
cancer aggressiveness [12–16]. The models showed strong correla-
tion with each other and generally predicted the same patients to be
PSA recurrences or systemic progressors. A recent comparison of
several breast cancer gene expression models by Fan et al. [42] also
showed high correlation between models. The implication is that
Table 6. Clinical variables included in clinical models
Clinical model
Clinical variable A B C
Revised Gleason score XXX
pStage XXX
Age at surgery XX
Preoperative PSA XX
Hormone or radiation therapy after RRP XX
Age at PSA recurrence X
Second PSA X
PSA slope X
doi:10.1371/journal.pone.0002318.t006
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cancer patients with similar clinical or biologic endpoints.
After the formal analysis was completed we began secondary
exploratory studies of the whole dataset. We hypothesized that
systemic progression beyond 5 years in the PSA controls might be
predicted by the models. When the 17 gene/probe model score
(and three of the other models) predicted a poorer outcome, there
was a high likelihood that a PSA control would have a positive
bone scan or CT beyond 5 years. There was also evidence
supporting a second hypothesis that prostate cancer-specific death
in the SYS cases might be predicted by the models. When the 17
gene/probe model score (and three of the other models) predicted
a poorer outcome, the median overall survival of a SYS case from
a positive bone scan or CT was 2.8 years (compared to 8.6 years
with a better model score). These secondary analyses imply that
tissue expression biomarker panels may have utility for the
stratification of patients for interventions at the time of PSA
recurrence as well as for systemic progression. Importantly, the
expression data was collected on primary tumor specimens
resected several years before the occurrence of the clinical events.
Overrepresentation of 8q24 is associated with clinically aggressive
prostate cancer (for example, references [43–45]). Furthermore,
tumor overexpression of genes on chromosome 8 (and from 8q24) is
also reproducibly associated with prostate cancer progression [46–
49].Werecentlymapped the region of 8q24 overrepresentation,and
it involves a ,5 Mb region surrounding c-Myc [50]. Our secondary
analyses demonstrated that 8q24 genes were significantly overrep-
resented in the top 68 and 126 genes by t-test and in the final 17
gene/probe model. Each of the genes exhibited similar magnitudes
of overexpression in the SYS cases suggesting an association with
chromosomal dosage. A common germline polymorphism mapped
near the c-Myc gene on 8q24, has recently been associated with
prostate cancer development [51]. This finding has been replicated
by at least five different groups, with the further suggestion that at
Figure 3. Systemic progression-free and overall prostate cancer-specific survival in the PSA control and SYS case groups. A) Systemic
progression-free survival for the patients classified in the poor outcome category and for those in the good outcome category in the PSA control
group–17 gene/probe model. B) Prostate cancer-specific overall survival for the patients classified in the poor outcome category and for those in the
good outcome category in the SYS case group–17 gene/probe model. C) Prostate cancer-specific overall survival for patients classified in the poor
outcome category and for those in the good outcome category in the SYS case group-Lapointe et al. 2004 recurrence model.
doi:10.1371/journal.pone.0002318.g003
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prostatecancerdevelopment[52–56].Itisnotknownifthemenwho
inherit the at-risk haplotype(s) have a clinically more aggressive
prostate cancer, a poorer prognosis, somatic (tumor) overrepresen-
tation of 8q24, or overexpression of 8q24 genes.
Alterations of several ets-family oncogenes are associated with
the development of prostate cancer [28–30]. Our panel(s) included
probe sets for three members of the ets family involved in prostate
cancer; ERG, ETV1, and ETV4, as well as their translocation
partner, TMPRSS2. As a group, these genes are over-expressed in
approximately 62% of prostate cancers. This overall prevalence
was nearly identical in our three case and control groups. In
addition, with the possible exception of ETV1, whose prevalence
of overexpression was about 2-fold higher in the SYS cases, none
of the genes seemed to be associated with systemic progression of
prostate cancer. It has been recently reported that ERG fusion is
associated with lethal prostate cancer in Scandinavian men treated
with watchful waiting [30]. However, the prevalence of fusion (and
presumably ERG overexpression) in that study was only 15%; far
lower than in our dataset and other reports [28,29]. These
differences are likely a result of the types of prostate cancer (and
clinical outcomes) diagnosed where PSA screening is common
(North America) and uncommon (Scandinavia).
We conclude that the measurement of gene expression patterns
may be useful for determining which men are likely to benefit from
additional therapy following PSA recurrence. These measure-
ments should be included in prospective evaluation of various
therapeutic interventions when PSA rises following definitive
treatment of prostate cancer.
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Figure S1 Summary of the nested case-control study design.
Found at: doi:10.1371/journal.pone.0002318.s001 (0.16 MB TIF)
Figure S2 Reproducibility of DASL assay and the effect of RNA
quantity on the DASL assay. A) An example of DASL interplate
reproducibility. B) Effect of reduced RNA quantity on the DASL
assay.
Found at: doi:10.1371/journal.pone.0002318.s002 (0.59 MB TIF)
Figure S3 Example results of the comparison of quantitative RT-
PCR and DASL data. ERG-Cancer Panel ver1 (A, R2=0.94),
ERG-Custom Panel (B, R2=0.94), PAGE4 (C, R2=0.89), MUC1
(D, R2=0.82) and FAM13C1 (E, R2=0.75). (F) Summary of
quantitative RT-PCR and DASL data comparisons.
Found at: doi:10.1371/journal.pone.0002318.s003 (0.48 MB TIF)
Figure S4 Comparison of genes having multiple probe sets on
the Cancer Panel v1 and/or the Custom panel. A) Comparison of
three probe sets (Cancer Panel ERG, Custom panel ERG and
Custom panel ERG splice variant) for ERG. B) Comparison of
two probe sets (Custom Panel SRD5A2 and Custom panel
terparbo) for SRD5A2/terparbo.
Found at: doi:10.1371/journal.pone.0002318.s004 (2.13 MB TIF)
Results S1 The Supplemental Results describe the replicate
analysis results, RT-PCR comparisons and inter- and intra-panel
gene expression comparisons.
Found at: doi:10.1371/journal.pone.0002318.s005 (0.05 MB
DOC)
Table S1 The List of Genes Included on the Commercially
Available Illumina DASL Cancer Panel v1. Prostate cancer
relevant genes are indicated (for selection criteria see footnotes
following Table S2).
Found at: doi:10.1371/journal.pone.0002318.s006 (0.11 MBXLS)
Table S2 Genes Relevant to Prostate Cancer Progression
Included on an Illumina DASL Custom Array (for selection
criteria see footnotes below).
Found at: doi:10.1371/journal.pone.0002318.s007 (0.16 MBXLS)
Table S3 Genes from Commercially Available Illumina
DASLTM Cancer Panel and Illumina DASL Custom Array
Ranked by Increasing P-Value.
Found at: doi:10.1371/journal.pone.0002318.s008 (0.21 MBXLS)
Table S4 Crame ´r’s V-statistic for selection between PSA
recurrence and systemic progression. All samples are included
(both training and validation sets). All models were augmented
with clinical information.
Found at: doi:10.1371/journal.pone.0002318.s009 (0.02 MB PDF)
Table S5 The Top 51 pathways associated with systemic
progression by Ingenuity Pathway Analysis.
Found at: doi:10.1371/journal.pone.0002318.s010 (0.03 MB
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Table S6 Association of genes on chromosome 8 with systemic
progression using Gene Set Enrichment Analysis (GSEA).
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Acknowledgments
Microarray data is available from the GEO database (http://www.ncbi.
nlm.nih.gov/geo/ accession number GSE10645). The authors appreciate
the advice and encouragement of Dr. Donald Tindall; PI of the Mayo
Prostate Cancer SPORE. Dr. John Cheville performed the blinded
regrading of the prostate cancers. The Mayo Clinic Cancer Center Tissue
and Cell Molecular Analysis Core (directed by Dr. Wilma Lingle) and
Genotyping Core (directed by Dr. Julie Cunningham) assisted with tissue
preparation and performed the expression analyses, respectively.
Author Contributions
Conceived and designed the experiments: RJ TK TN EB BD GK KB.
Performed the experiments: TK TN. Analyzed the data: YA RJ TK TN
BM SA EB KB. Contributed reagents/materials/analysis tools: YA RJ TK
BM SA EB KB. Wrote the paper: RJ TN KB.
Figure 4. Expression results for ERG, ETV1 and ETV4 among
the men with no evidence of disease progression (NED), PSA
recurrence (PSA) and systemic progression (SYS). (A) Each
overlapping set of three bars (blue, red and green) represent a different
case or control. Thresholds for overexpression are ERG.3200,
ETV1.6000 and ETV4.1400. (B) The numbers of cases showing
overexpression of one or more of ERG, ETV1 and ETV4 are shown.
doi:10.1371/journal.pone.0002318.g004
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